Liljas B[au] - Search Results

Year	Number of Results
1997	2
1998	5
2000	3
2001	3
2003	3
2004	3
2005	2
2006	1
2008	2
2009	1
2010	3
2011	1
2022	1
2023	0

1

Insurance and imperfect financial markets in Grossman's demand for health model--a reply to Tabata and Ohkusa.

Liljas B. Liljas B. J Health Econ. 2000 Sep;19(5):821-7. doi: 10.1016/s0167-6296(00)00034-5. J Health Econ. 2000. PMID: 11184807

2

Is asthma self-management cost-effective?

Liljas B, Lahdensuo A. Liljas B, et al. Patient Educ Couns. 1997 Dec;32(1 Suppl):S97-104. doi: 10.1016/s0738-3991(97)00101-8. Patient Educ Couns. 1997. PMID: 9516765 Review.

3

Measuring costs in cost-utility analyses. Variations in the literature.

Stone PW, Chapman RH, Sandberg EA, Liljas B, Neumann PJ. Stone PW, et al. Among authors: liljas b. Int J Technol Assess Health Care. 2000 Winter;16(1):111-24. doi: 10.1017/s0266462300161100. Int J Technol Assess Health Care. 2000. PMID: 10815358 Review.

4

On individual preferences and aggregation in economic evaluation in healthcare.

Liljas B, Lindgren B. Liljas B, et al. Pharmacoeconomics. 2001;19(4):323-35. doi: 10.2165/00019053-200119040-00001. Pharmacoeconomics. 2001. PMID: 11383750 Review.

5

Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.

Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, Reed S. Ramsey S, et al. Among authors: liljas b. Value Health. 2005 Sep-Oct;8(5):521-33. doi: 10.1111/j.1524-4733.2005.00045.x. Value Health. 2005. PMID: 16176491 Free article. Review.

6

Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors.

Gaitonde P, Chirikov V, Kelkar S, Liljas B. Gaitonde P, et al. Among authors: liljas b. Cancer Manag Res. 2022 Dec 7;14:3421-3435. doi: 10.2147/CMAR.S380857. eCollection 2022. Cancer Manag Res. 2022. PMID: 36514307 Free PMC article.

7

The demand for health with uncertainty and insurance.

Liljas B. Liljas B. J Health Econ. 1998 Apr;17(2):153-70. doi: 10.1016/s0167-6296(97)00021-0. J Health Econ. 1998. PMID: 10180913

8

Welfare, QALYs, and costs - a comment.

Liljas B. Liljas B. Health Econ. 2011 Jan;20(1):68-72. doi: 10.1002/hec.1600. Health Econ. 2011. PMID: 21157833

9

Perceptions and preferences of autologous blood donors.

Lee SJ, Liljas B, Churchill WH, Popovsky MA, Stowell CP, Cannon ME, Johannesson M. Lee SJ, et al. Among authors: liljas b. Transfusion. 1998 Aug;38(8):757-63. doi: 10.1046/j.1537-2995.1998.38898375515.x. Transfusion. 1998. PMID: 9709784

10

On the welfare theoretic foundation of cost-effectiveness analysis-the case when survival is not affected.

Liljas B. Liljas B. Eur J Health Econ. 2010 Feb;11(1):5-13. doi: 10.1007/s10198-009-0145-6. Epub 2009 Mar 3. Eur J Health Econ. 2010. PMID: 19255794

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results